There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - Senate

Short Title(s) as Introduced

MMEDS Act of 2020
Medical Manufacturing, Economic Development, and Sustainability Act of 2020

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to rescue domestic medical product manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions.


Actions Overview (1)

Date Actions Overview
08/06/2020Introduced in Senate

All Actions (1)

Date All Actions
08/06/2020Read twice and referred to the Committee on Finance.
Action By: Senate

Cosponsors (0)

No cosponsors.


Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
Senate Finance08/06/2020 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Latest Summary (1)

There is one summary for S.4467. View summaries

Shown Here:
Introduced in Senate (08/06/2020)

Medical Manufacturing, Economic Development, and Sustainability Act of 2020 or the MMEDS Act of 2020

This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical product manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical product manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical product manufacturers..

The bill also directs the Department of Health and Human Services to study the extent to which the health of aging individuals and vulnerable populations have been disproportionately harmed by the COVID-19 (i.e., coronavirus disease 2019) pandemic and prior epidemics and pandemics.